

CiplaQCi

CIPLA QUALITY CHEMICAL INDUSTRIES LTD

WORLD HEPATITIS DAY 2017

A Look at Hepatitis

Hepatitis is an inflammation of the liver caused by a virus and there are 5 different types of Hepatitis (A, B, C, D and E). Hepatitis B and C are the more severe types that lead to chronic illness and are the most common cause of liver cirrhosis and cancer.

Hepatitis B in particular is a global health problem with about 240 million people infected with the Hepatitis B virus (HBV). According to the Ministry of Health, Uganda has one of the highest prevalence rates of Hepatitis B in the world with rates of infection particularly high in Karamoja Region, Northern Uganda, West Nile and Western Uganda and prevalence rates as high as 23%. It is for this reason that Cipla Quality Chemical Industries (CiplaQCIL) decided to start manufacturing Hepatitis B medicines in order to provide ready and affordable treatment for Ugandans.

Access to Hepatitis B Medicines in Uganda

CiplaQCIL last year launched Tenofovir (Tenofovir), the first Hepatitis B medicine to be produced in Africa and shortly after went on to produce Zentair (Entecavir).

CiplaQCIL last year launched Entecavir, the first Hepatitis B medicine to be produced in Africa.

Tenofovir is the recommended first line treatment by the World Health Organization (WHO) in management of the disease.

Entecavir is a recommended second line treatment. Hepatitis B patients in Uganda have been typically treated with ARVs but this method has proven to be costly in the management of the disease. They have led to cross-resistance in some cases and also their usage for Hepatitis B treatment could lead to ARV shortages.

Texavir and Zentair come in as a solution to address those possible shortcomings.

Other Efforts in Fighting Hepatitis


CiplaQCIL has supported and continues to work closely with the Ministry of Health in sensitization efforts across the country to bring awareness and understanding about the disease.

Additionally, CiplaQCIL has future plans to manufacture medicine for Hepatitis C.

Commitment

As we commemorate World Hepatitis Day this year under the theme, "Elimination," CiplaQCIL reaffirms its commitment to fight Hepatitis by guaranteeing quality and excellence in every tablet that we manufacture and producing newer medicines to effectively fight the disease.

CiplaQCIL is a WHO approved facility and remains a trusted partner in the fight against Hepatitis.



Packing of medicines



Coating of ARVs

